TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05723341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0,25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0,25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
Study: NCT04989621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and Rituximab
Description: Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg po qd
Study: NCT05012735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
Study: NCT05861674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-003(20mg/kg)
Description: 20 mg/kg Q2W intravenously for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-003(10mg/kg)
Description: 10 mg/kg Q2W intravenously for 48 weeks
Study: NCT05012735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Ultrathin Hydrocolloid Bandage
Description: Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
Study: NCT06243081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group (Flipped Teaching Method Group)
Description: Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory.
Study: NCT05402631

Intervention type: PROCEDURE
Intervention: Epidural Injection
Description: patient receives an epidural injection due to lower back pain

Intervention type: PROCEDURE
Intervention: Epidural Injection
Description: patient receives an epidural injection due to lower back pain

Intervention type: PROCEDURE
Intervention: Periradicular Injection
Description: patient receives a periradicular injection due to lower back pain

Intervention type: PROCEDURE
Intervention: Periradicular Injection
Description: patient receives a periradicular injection due to lower back pain
Study: NCT06515444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes program
Description: The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes program
Description: The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 minutes program
Description: The curriculum component offers 10-minute daily doses of activities targeting the development of eight socioemotional competences in children: (i) emotional knowledge and management, (ii) developing a healthy identity, (iii) establishing and maintaining positive relationships, (iv) feeling and showing empathy, (v) establishing and reaching goals, (vi) responsible decision-making, (vii) contributing to the community and (viii) developing spirituality. The activities do not require the teacher to plan or to prepare material for the students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 hour PD program
Description: The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 hour PD program
Description: The professional development (PD) component is a 1-hour dose of activities targeting each of the eight SECs on which the curriculum focuses. The focus of PD is not to teach about SEC development in children but to develop SEC in teachers. Thus, this is an 8-hour PD program distributed throughout the academic year.
Study: NCT05402319

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Description: Anti-infective treatment with at least two different types of sensitive antibiotics.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Description: Anti-infective treatment with at least two different types of sensitive antibiotics.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Description: Anti-infective treatment with at least two different types of sensitive antibiotics.
Study: NCT05554874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Description: receiving Pulsed electromagnetic fields 3 times, immediately after the onset of delayed muscle soreness, 24 and 48 hours later.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed electromagnetic fields
Description: Sham application will be applied with the same device without applying magnetic current.
Study: NCT05861674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
Study: NCT06039098

Intervention type: DEVICE
Intervention: DCS
Description: DCS monitoring of brain
Study: NCT05861674

Intervention type: DRUG
Group type: OTHER
Intervention: TAF
Description: TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
Study: NCT05011019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846 capsules
Description: AL2846 is a multi-target receptor tyrosine kinase inhibitor.
Study: NCT05436782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercises
Description: •Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: •Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
Study: NCT06334978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic intervention
Description: The experimental group received the same treatment as the control group and one osteopathic intervention per week for the 21 days of the study (days 2, 9 and 16). Each session was performed on a different day from the conventional treatment to prevent interactions. The physiotherapist performed an osteopathic assessment involving a static/dynamic inspection and palpation and other osteopathic tests: Mitchell test, Quick Scanning, standing flexion (Piedallu) test, Gillet test, sphenobasilar synchondrosis (SBS) test, sutural palpation test and diaphragm test. Techniques used: the dog technique in flexion, scalene muscle energy technique, Jones' first rib adjustment, first rib trust in posterior subluxation, occipitomastoid thrust, Sutherland's posterior needle-scratch, SBS decompression, semi-direct thrust for the sacrum, Sutherland's sacrum, posterior occipital condyle thrust, SBS equilibration.
Study: NCT06535061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: white noise
Description: The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
Study: NCT05459168

Intervention type: OTHER
Group type: OTHER
Intervention: Calm Meditation Smartphone App Feedback
Description: Advisory committee members will be asked to use the current Calm meditation app platform for a full week and to keep an informal journal prior to participating in focus groups in which they will provide feedback about the app.

Intervention type: OTHER
Group type: OTHER
Intervention: Cancer-Specific Meditation App Prototype Design
Description: Findings from Aim 1 will inform the development of a cancer-specific meditation app prototype to be tested in Aim 3.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cancer-Specific Meditation App Prototype
Description: Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
Study: NCT04821570

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Per recommended dosing schedule
Study: NCT06535061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white noise
Description: The experimental group was exposed to a white noise sound combined from 4 different sounds: ultrasound heartbeat sound, wave sound, vacuum cleaner sound and hair removal machine sound at 50 dBSPL 5 minutes before the procedure. The experimental group was exposed to white noise for a total of 15 minutes before, during and after the procedure. At the same time, the newborn in the experimental group I was given a pacifier.
Study: NCT06534190

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-Df-crefmirlimab PET scan
Description: 89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immunotherapy treatment with Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Immunotherapy treatment with cetrelimab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconium Zr 89 crefmirlimab berdoxam
Description: 89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
Study: NCT04972955

Intervention type: DEVICE
Intervention: Freestyle Libre 2
Description: Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.

Intervention type: DEVICE
Intervention: Freestyle Libre 2
Description: Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.
Study: NCT06100497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Mainly used for neoadjuvant treatment and subsequent adjuvant or maintenance treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Mainly used for neoadjuvant treatment and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Mainly used for neoadjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Mainly used for neoadjuvant treatment
Study: NCT05213845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spine flexion/extension active range of motion exercises
Description: Five full active range of motion rehabilitation sessions will be scheduled. Four or the five following full active range of motion exercises will be performed during one rehabilitation session : spine flexion and extension (quadrupedic position), lumbar flexion and extension (sitting position), posterior and anterior pelvic tilt (sitting and standing position), lumbar flexion and extension (standing position) and Jefferson Curl exercise. All five rehabilitation sessions must be performed within 60 days
Study: NCT06374602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Lenvatinib
Description: Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Study: NCT06094153

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consume placebo (Maltodextrin) once daily before going to bed for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO 1
Description: Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO 2
Description: Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
Study: NCT04821570

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Per recommended dosing schedule

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Per recommended dosing schedule

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Per recommended dosing schedule

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Per recommended dosing schedule
Study: NCT05636774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heart failure medication
Description: Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tables / infusion
Study: NCT05355337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: 9 weeks of treatment with Pramipexole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 weeks of treatment with Placebo
Study: NCT04676516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 is a first-in-class small molecule PRMT5 inhibitor in form of an oral capsule.
Study: NCT05862519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reset
Description: Pure for Men Reset is a Vegan, Proprietary Blend of Toxin Eliminating Cleanser: Cascara Sagrada Bark, Senna Leaf, Psyllium Husk, Licorice Root, and Aloe Vera Gel. Taken on Day 1 to Day 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stay Ready Fiber
Description: Stay Ready Fiber is a Vegan, 100% Natural, Proprietary Blend of Digestive Aids: Psyllium Husk, Aloe Vera Extract, Chia Seeds \& Flaxseed. Taken from Day 7 through Day 21.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Libido
Description: Supplement designed to support endurance and increased arousal. Contains L-Citrulline, L-Arginine and Black Pepper Fruit Extract (Piper Nigrum). Taken from Day 7 through to Day 28.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testosterone supplement
Description: Supplement designed to enhance testosterone production. Contains Ashwagandha, Zinc, Vitamin D, Maca, and Tongkat Ali. Taken from Day 28 through Day 84.
Study: NCT04958629

Intervention type: OTHER
Intervention: familial hypercholesterolemia
Description: Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
Study: NCT06047366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine w/ epi
Description: Septodont's standard formulation of 2% lidocaine with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine w/ epi
Description: Septodont's standard formulation of 2% lidocaine with epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine w/ epi
Description: Septodont's standard formulation of 4% articaine with epinephrine
Study: NCT05984147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR108
Description: 3 Days dosing, and 4 days no dose in a week
Study: NCT06566131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified mobile health app
Description: Participants will receive visualized instructions about the PW use (e.g., search and download the app on App Store, navigate and understand key features, play puzzle games, and track step counts). During the 6-week intervention period, participants will receive reminders on wearing the accelerometer, using the app for potential incentives, and engaging in regular physical activities for health promotion.
Study: NCT05588089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers.
Study: NCT05078450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Lifters
Description: Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Lifters
Description: Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
Study: NCT06412315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
Study: NCT06124599

Intervention type: OTHER
Intervention: Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period
Description: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other

Intervention type: OTHER
Intervention: Identification of symptoms of menstrual in control patient in the last three menstrual period
Description: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
Study: NCT05452005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-αvβ6-BP
Description: Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.